Panacea Biotec inks agreement with Natco Pharma, Breckenridge Pharmaceutical

27 Aug 2018 Evaluate

Panacea Biotec has entered into a tripartite agreement with Natco Pharma and Breckenridge Pharmaceutical Inc. for the manufacture and supply of Azacitidine Injection for the US market under Breckenridge's already-approved ANDA. Azacitidine is a generic equivalent of Vidaza, which is marketed by Celgene Corporation, US.

As per the terms of the agreement, Natco has provided the technology for manufacturing Azacitidine to Panacea Biotec's facility located at Baddi in the state of Himachal Pradesh. Panacea Biotec will be responsible for manufacture and supply of the product, which will be marketed, sold and distributed by Breckenridge in the US.

Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities. It is one of the largest vaccine producers and biotechnology companies in India.

Panacea Biotec Share Price

407.05 48.55 (13.54%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×